Company news
Bioinvent International Ab (OMXSTO:BINV) news
Bioinvent International Ab news releases on 6ix. Latest, Jun 1, 2026: BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206…
Press releases & updates
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
June 1, 2026
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
May 12, 2026
BioInvent International AB: Interim Report January - March 2026
April 29, 2026
BioInvent International AB Publishes Annual Report 2025
March 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
March 26, 2026
Notice to Annual General Meeting in BioInvent International AB
March 24, 2026
BioInvent International AB: Year-End Report January 1 - December 31, 2025
February 26, 2026
Invitation to Presentation of BioInvent's Year-End Report 2025
February 26, 2026
BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting
February 23, 2026
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
January 5, 2026
BioInvent to Participate in Upcoming Investor Conference
December 18, 2025
BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors
November 18, 2025
EMA Positive Opinion for Orphan Drug Designation to BioInvent's BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma
November 17, 2025
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025
November 3, 2025
BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025
November 3, 2025
BioInvent International AB: Interim Report January - September 2025
October 29, 2025
Invitation to Presentation of BioInvent's Interim Report January - September 2025
October 27, 2025
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
October 13, 2025
BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma
October 8, 2025
BioInvent to Present Phase 1 Clinical Data for BI-1910, a TNFR2 Agonist for the Treatment of Solid Tumors, at SITC
October 3, 2025
BioInvent Announces Board of Directors Update
September 2, 2025
BioInvent International AB: Interim Report January - June 2025
August 26, 2025
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation
August 26, 2025
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
July 28, 2025
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
June 12, 2025
BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors
June 11, 2025
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
May 27, 2025
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
May 14, 2025
Resolutions at BioInvent's Annual General Meeting 2025
April 29, 2025